Abstract:
A wound dressing laminate (2, 2a, 2b) serves especially to manufacture body-shape wound dressings. The wound dressing laminate comprises a wound-facing non-woven layer (7a, 7b) composed of non-thermoplastic carboxymethyl cellulose fibres (8) which are combined into a coherent laminate structure with a non-woven backing layer (9a, 9b) composed of thermoplastic fibres (10) selected from the group of fibres comprising polyurethane fibres, hydrophobic polypropylene fibres and/or spunlaced fibres. The wound-facing non-woven layer (7a, 7b) and the non-woven backing layer (9a, 9b) are laminated together by needle-punching.
Abstract:
A wound care dressing comprising at least a separating film layer sheet (2) having a topside (4) and a bottom side (3) both provided with an adhesive (5,6), a hydrogel layer sheet (7) attached to the bottom side (3) of the separating film layer sheet (2) to form a combined matrix layer (16), and where the matrix layer (16) has a plurality of perforations (9), serves for improved wound care regime in particular when used at moist and/or exuding wounds. A foam layer sheet (14a) is attached to the topside (4) of the separating layer sheet (2) and covered by a cover film layer sheet (14b; 43) to allow fluid to pass via the perforations (9) into the foam layer sheet (14a) and to evaporate through the cover film layer sheet (14b;43). A method and a production line are also disclosed. Preferred embodiments include perforations made by means of ultrasound.
Abstract:
A method of manufacturing a pharmaceutical active prepolymer formulation includes the steps of combining in a reactor at least one polyol compound, at least one aromatic di-isocyanate compound, and/or at least one aliphatic di-isocyanate compound, and a pharmaceutical active agent having a water or moisture content of maximum 1.0 wt/wt%. Then the at least one polyol compound and/or the at least one di-isocyanate compound is allowed to prepolymerize to integrate the pharmaceutical active agent to obtain the pharmaceutical active prepolymer formulation. The pharmaceutical active prepolymer formulation can be made into a foam for use in pharmaceutical active wound dressings.
Abstract:
A wound dressing laminate (1') comprises a layer (3) impregnated with an antimicrobial agent (4) inserted between an apertured wound-contacting layer (2) and an absorbent non-woven layer (5;6). Wound dressings made of the wound dressing laminate prevent infection of a wound, do not induce maceration, and absorb exudates at controlled level so as to continuously cleanse the wound bed without drying the wound. Manual cleansing during dressing changes, if any at all, is usually not necessary and significant nursing time can be saved. The laminate is manufactured using the steps of providing the layer (3) impregnated with an antimicrobial agent (4), providing an apertured wound-contacting layer (2) adjacent one side of the layer (3) impregnated with the antimicrobial agent (4), providing an absorbent non-woven layer (5) adjacent the opposite side of the layer (3) impregnated with the antimicrobial agent (4), and laminating the layers (2;3;5) together mechanically.
Abstract:
A wound dressing (1;15;18) comprising a polyurethane film sheet (2;19) having a wound facing side (3) and an opposite side (4). The wound facing side (3) has a peripheral rim zone (5) provided with an adhesive (6) or an adhesive means (16), the peripheral rim zone (5) encircles a central sheet part (11) free of adhesive (6) or adhesive means (16), and the wound dressing (1) has a moisture vapor transmission rate of at least 1,200 g/m 2 /24 hour at the adhesive- coated or adhesive-means provided rim zone (5) and a moisture vapor transmission rate at the central sheet part (12) of at least 3,000 g/m 2 /24 hour. A method and production line for manufacturing various embodiments of wound dressings are also disclosed.
Abstract translation:1.一种伤口敷料(1; 15; 18),包括具有面向伤口的侧面(3)和相对侧(4)的聚氨酯膜片(2; 19)。 伤口面对侧(3)具有设置有粘合剂(6)或粘合装置(16)的外围边缘区域(5),周边边缘区域(5)围绕不含粘合剂(6)的中心片部分 )或粘合剂装置(16),并且伤口敷料(1)在粘合剂涂覆或粘合剂装置的边缘区域(5)处具有至少1200g / m 2/24小时的湿气透过率和湿气 中心片部分(12)处的蒸汽透过率至少为3,000g / m 2/24小时。 还公开了用于制造伤口敷料的各种实施例的方法和生产线。